Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

BIONOMICS LIMITED Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 6-K Quarterly results
09/28/2023 6-K Quarterly results
07/31/2023 6-K Quarterly results
07/28/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Shareholder communication on the De-listing process Bionomics Limited , , a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, refers to its Announcement released to the ASX on 25 July 2023 titled “Bionomics announces voluntary delisting”. In accordance with ASX Listing Rules 3.17, please find attached the copies of the following documents being sent to Shareholders today: • a letter giving information about the de-listing process and the options available to Shareholders, and • an ADS Conversion Facility Election Form. Released on authority of the Company Secretary. FOR FURTHER INFORMATION PL...",
"ABN 53 075 582 740 28 July 2023 MR SAM SAMPLEFLAT 123123 SAMPLE STREETTHE SAMPLE HILLSAMPLE ESTATE"
07/25/2023 6-K Quarterly results
07/24/2023 6-K Quarterly results
07/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Entity name BIONOMICS LIMITED Announcement Type New announcement Date of this announcement Friday July 07, 2023 Details of +securities that have ceased Number of ASX +security +securities that The +securities have Date of code Security description have ceased ceased due to cessation BNOAO OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES BNOAO OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES 378,600 Expiry of option or other convertible security without exercise or conversion 3,500,000 Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied 25/05/2023 30/06/2023 Refer to next page for full details of the announcement Exhibit 99.1 Notification of cessation of +securities 1 / 4 Exhibit 99.1 Notification of cessation of +securit..."
07/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABN 53 075 582 740 ASX ANNOUNCEMENT 28 April 2023 Quarterly Activities and Cashflow Report Bionomics Limited , a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 31 March 2023 and up to the date of this announcement include: • On 1 January 2023, Errol B. De Souza, Ph.D., assumed the role of Non-Executive Chairman of the Board of Directors. Dr. De Souza had previously served as Bionomics’ Executive Chairman from November 2018 through 31 December 2022. • On 5 January 2023, Spyridon “Spyros” Papapetr..."
07/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABN 53 075 582 740 ASX ANNOUNCEMENT 3 July 2023 Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth • Alan Fisher appointed Chair of the Board of Directors • Tim Cunningham joins as Chief Financial Officer Bionomics Limited , a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive member of the Board since 1 September 2016 and Chair of the..."
04/27/2023 6-K Quarterly results
03/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Bionomics Reports Promising Update on Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder • Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challenge • Results achieved statistical significance in post-hoc analysis of the full data set and in relevant subpopulations • Favourable safety, tolerability and PK findings are consistent with a fast-acting non-sedating anxiolytic profile • The company is planning an End of Phase 2 meeting to discuss BNC210’s late-stage SAD program 2H 2023 • Webcast and conference call scheduled for Thursday, March 9, 2023 at 8:00 AM EST Bionomics Limited , , a clinical-stage biopharmaceutical company developing novel allosteric ion channe..."
02/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Bionomics Limited ABN 53 075 582 740 We give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Dr Errol De Souza Date of last notice 28 November 2022 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph of the definition ...",
"Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Bionomics Limited ABN 53 075 582 740 We give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Spyridon Papapetropoulos Date of last notice 9 January 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph of the defini..."
02/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Half-year 31 December 2022 31 December 2021 Net tangible asset backing per ordinary share 2.02 cents 2.90 cents Page 2 of 26 ABN 53 075 582 740 ASX ANNOUNCEMENT 23 February 2023 BIONOMICS’ HALF-YEAR REPORT Adelaide, Australia: Bionomics Limited , today announced its FY2023 report for the half-year ended 31 December 2022. This period represented a transformational time for Bionomics in which the Company made great strides on multiple fronts, including progress on advancing the pipeline, raising capital, and implementing strategic corporate initiatives designed to create long-term shareholder value. The Company recently completed its Phase 2 PREVAIL Study to evaluate BNC210 for the acute treatment of Social Anxiety Disorder . The PREVAIL Study, initiated in January 2022, was a randomised, do..."
01/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABN 53 075 582 740 ASX ANNOUNCEMENT 30 January 2023 Quarterly Activities and Cashflow Report Bionomics Limited , a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the Quarter ended 31 December 2022 and up to the date of this announcement include: • On 4 October 2022, Bionomics announced that it would be attending the Cantor Neurology & Psychiatry Conference including Bionomics’ Executive Chairman, Dr. Errol De Souza’s participation in the “Emerging Broad Pipeline for Psychiatric Indications Does Not Weigh on Our Minds” p..."
01/18/2023 6-K Quarterly results
01/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Appendix 3X Initial Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity BIONOMICS LIMITED ABN 075 582 740 We give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Spyridon Papapetropoulos Date of appointment 5 January 2023 Part 1 - Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragr...",
"Entity name BIONOMICS LIMITED Announcement Type New announcement Date of this announcement Monday January 09, 2023 Details of +securities that have ceased Number of ASX +security +securities that The +securities have Date of code Security description have ceased ceased due to cessation BNOAO OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES BNOAO OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES BNOAO OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES BNOAO OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES BNOAO OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES 200,000 Expiry of option or other convertible security without exercise or conversion 4,000 Expiry of option or other convertible security without exercise or conversion 5,000 Expiry of option or other convertible security without exercise or ..."
12/19/2022 6-K Quarterly results
12/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABN 53 075 582 740 ASX ANNOUNCEMENT 16 December 2022 Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer Experienced biotech executive to lead the next phase of growth Bionomics Limited , a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, today announced that it has appointed Spyridon “Spyros” Papapetropoulos, M.D. as President and Chief Executive Officer , effective 5 January 2023. Errol B. De Souza, Ph.D., who has been serving as Bionomics’ Executive Chairman since November 2018, will continue in his role through 31 December 2022 to ensure a seamle..."
11/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABN 53 075 582 740 16 November 2022 ASX Market Announcements ASX Limited Level 4 Stock Exchange Centre 20 Bridge Street SYDNEY NSW 2000 Dear Sir/Madam, RESULTS OF ANNUAL GENERAL MEETING In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the attached document provides details of the proxies received and the manner in which votes were cast for each resolution. This announcement was authorised for release by the Company Secretary. FOR FURTHER INFORMATION PLEASE CONTACT: Ms Suzanne Irwin Company Secretary +61 8 8150 7400 [email protected] About Bionomics Limited Bionomics is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system d..."
10/25/2022 6-K Quarterly results
10/18/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABN 53 075 582 740 ASX ANNOUNCEMENT"
10/18/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given that the Annual General Meeting of Shareholders of Bionomics Limited will be held on Wednesday, 16 November 2022 at 9.30am . Recent legislative changes to the Corporations Act 2001 mean there are new options available to shareholders as to how the communication from the Company can be received. The Company will not be dispatching physical copies of meeting documents and notices, including the Notice of Meeting for the AGM, unless you request a physical copy to be posted to you. The Notice of Meeting, accompanying explanatory statement and Annual Report are being made available to shareholders electronically. This means that: • You can access the Meeting Materials online at the Company’s website www.bionomics.com.au or at the Co...",
"SRN/HIN: I9999999999 BNO MR SAM SAMPLE FLAT 123 123 SAMPLE STREET THE SAMPLE HILL SAMPLE ESTATE SAMPLEVILLE VIC 3030 ABN 53 075 582 740 XX",
"Entity name BIONOMICS LIMITED Announcement Type New announcement Date of this announcement 17/10/2022 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue Maximum Number of ASX +security code +Security description +securities to be issued BNO ORDINARY FULLY PAID 900,000,000 Proposed +issue date 16/2/2023 Refer to next page for full details of the announcement Proposed issue of securities 1 / 6 Proposed issue of securities Part 1 - Entity and announcement details 1.1 Name of +Entity BIONOMICS LIMITED We give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities on a +deferred settlement basis, we agree to the matters set out in Appen..."
10/06/2022 6-K Quarterly results
10/04/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABN 53 075 582 740 ASX ANNOUNCEMENT"
09/21/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABN 53 075 582 740 ASX ANNOUNCEMENT"
08/25/2022 6-K Quarterly results
08/08/2022 6-K Quarterly results
07/29/2022 6-K Quarterly results
07/20/2022 6-K Quarterly results
07/05/2022 6-K Quarterly results
06/13/2022 6-K Quarterly results
05/18/2022 6-K Quarterly results
05/16/2022 6-K Quarterly results
04/29/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ABN 53 075 582 740 ASX ANNOUNCEMENT 29 April 2022 Quarterly Activities and Cashflow Report Bionomics Limited , a global, clinical stage biopharmaceutical company, today released its Appendix 4C – Quarterly Cashflow Report. Highlights during the quarter ended 31 March 2022 and up to the date of this announcement include: • On 4 January 2022, the Company announced that it had initiated its Phase 2 clinical trial to evaluate BNC210 for the acute treatment of Social Anxiety Disorder , with topline results expected by the end of 2022. • On 6 January 2022, Bionomics announced that it closed its US$23 million US securities offering following the full exercise of the underwriters’ option to purchase additional ADSs. • On 6 January 2022, the Company also announced that it would..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy